Clinical Trial: Standard-dose or induction-dose radiotherapy combined with adebelimumab and chemotherapy for locally advanced esophageal squamous cell carcinoma: A non-randomized, dual-cohort, phase II clinical trial (China)

China, Sept. 7 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Standard-dose or induction-dose radiotherapy combined with adebelimumab and chemotherapy for locally advanced esophageal squamous cell carcinoma: A non-randomized, dual-cohort, phase II clinical trial'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600131718

Registration Time: 2026/09/06

Type: Interventional study

Primary Sponsor: The Affiliated Hospital of Qingdao University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=341623

Published by HT Digital Content Services with permission from Health Daily Digest....